CD274 and neoplasm: Intratumor heterogeneity most likely contributes to the ambiguous results on PD-L1 status seen in the Checkmate6 and Keynote8 studies of HNSCC patients and challenges the use of PD-L1 expression from single tumour biopsies as a predictor for immunotherapy in HNSCC patients.